Follow

"The FDA is letting the industry know that it’s interested in streamlining the accelerated approval process for new cancer drugs, but that they’re not interested in making it too easy, either. They’re open to the idea of a “one-trial” route to such approvals, but it had better be a good trial."

science.org/content/blog-post/

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.